THE HUMAN-IMMUNODEFICIENCY-VIRUS LONG TERMINAL REPEAT INCLUDES A SPECIALIZED INITIATOR ELEMENT WHICH IS REQUIRED FOR TAT-RESPONSIVE TRANSCRIPTION

被引:56
作者
RITTNER, K [1 ]
CHURCHER, MJ [1 ]
GAIT, MJ [1 ]
KARN, J [1 ]
机构
[1] MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND
关键词
HUMAN IMMUNODEFICIENCY VIRUS; TAT; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; INITIATOR (INR) ELEMENT;
D O I
10.1006/jmbi.1995.0243
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effects of mutations in human immunodeficiency virus type-1 (HIV-1) long terminal repeat on initiation and on Tat-mediated trans-activation were studied using cell-free transcription assays. All the elements that are necessary for efficient transcription initiation in vitro are included in the core promoter. This region contains three tandem Sp1 binding sites, a TATA element and an initiator (INR) sequence. Although the HIV-1 INR element overlaps the trans-activation response region (TAR), it forms an integral part of the promoter. The HIV-1 INR element was characterised in detail using a template that carries a complete HIV-1 promoter and a displaced TAR RNA element. The results demonstrate that the sequence G(+1)GGTCT is essential for HIV-1 INR function. RNase protection experiments show that Tat acts exclusively to stimulate transcriptional elongation. Mutations in the core promoter elements reduce initiation rates dramatically but do not block Tat activity. For each mutation studied, the total level of transcription in the presence of Tat is proportional to the rate of initiation in the absence of Tat. Furthermore the rate of initiation remains constant in the presence or absence of Tat. We conclude that the elements of the HIV-1 core promoter act in concert to simulate initiation. By contrast, Tar acts independently of the core promoter elements and stimulates elongation. The data strongly suggest that Tat is recruited to the elongating transcription complex during its transit through TAR.
引用
收藏
页码:562 / 580
页数:19
相关论文
共 72 条
[1]   PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE [J].
ADACHI, A ;
GENDELMAN, HE ;
KOENIG, S ;
FOLKS, T ;
WILLEY, R ;
RABSON, A ;
MARTIN, MA .
JOURNAL OF VIROLOGY, 1986, 59 (02) :284-291
[2]   TRANSCRIPTIONAL ELONGATION BY PURIFIED RNA POLYMERASE-II IS BLOCKED AT THE TRANS-ACTIVATION-RESPONSIVE REGION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INVITRO [J].
BENGAL, E ;
ALONI, Y .
JOURNAL OF VIROLOGY, 1991, 65 (09) :4910-4918
[3]   TAT TRANS-ACTIVATES THE HUMAN IMMUNODEFICIENCY VIRUS THROUGH A NASCENT RNA TARGET [J].
BERKHOUT, B ;
SILVERMAN, RH ;
JEANG, KT .
CELL, 1989, 59 (02) :273-282
[4]   FUNCTIONAL ROLES FOR THE TATA PROMOTER AND ENHANCERS IN BASAL AND TAT-INDUCED EXPRESSION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 LONG TERMINAL REPEAT [J].
BERKHOUT, B ;
JEANG, KT .
JOURNAL OF VIROLOGY, 1992, 66 (01) :139-149
[5]   TAR-INDEPENDENT ACTIVATION OF THE HIV-1-LTR - EVIDENCE THAT TAT REQUIRES SPECIFIC REGIONS OF THE PROMOTER [J].
BERKHOUT, B ;
GATIGNOL, A ;
RABSON, AB ;
JEANG, KT .
CELL, 1990, 62 (04) :757-767
[6]   HIGH-AFFINITY BINDING OF TAR RNA BY THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TAT PROTEIN REQUIRES BASE-PAIRS IN THE RNA STEM AND AMINO-ACID-RESIDUES FLANKING THE BASIC REGION [J].
CHURCHER, MJ ;
LAMONT, C ;
HAMY, F ;
DINGWALL, C ;
GREEN, SM ;
LOWE, AD ;
BUTLER, PJG ;
GAIT, MJ ;
KARN, J .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 230 (01) :90-110
[7]  
CHURCHER MJ, 1995, IN PRESS P NATL ACAD
[8]   DOES HIV-1 TAT INDUCE A CHANGE IN VIRAL INITIATION RIGHTS [J].
CULLEN, BR .
CELL, 1993, 73 (03) :417-420
[9]   TRANSACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS OCCURS VIA A BIMODAL MECHANISM [J].
CULLEN, BR .
CELL, 1986, 46 (07) :973-982
[10]   CONSERVED NUCLEOTIDES IN THE TAR RNA STEM OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ARE CRITICAL FOR TAT BINDING AND TRANSACTIVATION - MODEL FOR TAR RNA TERTIARY STRUCTURE [J].
DELLING, U ;
REID, LS ;
BARNETT, RW ;
MA, MYX ;
CLIMIE, S ;
SUMNERSMITH, M ;
SONENBERG, N .
JOURNAL OF VIROLOGY, 1992, 66 (05) :3018-3025